Zhonghong Eric Guan

Company: Mural Oncology

Job title: SVP, Head of Medical Affairs

Seminars:

Exploring Nemvaleukin Alfa Monotherapy & in Combination With Pembrolizumab in Patients With Advanced Solid Tumors 11:30 am

Outlining nemvaleukin as a novel engineered cytokine Revealing the design to selectively bind to intermediate-affinity interleukin-2 receptor (IL-2R) for preferential activation and expansion of tumor-killing CD8+ T cells and natural killer (NK) cells, with minimal expansion of regulatory T cells (Tregs) Discussing the potential to reduce native IL-2’s toxicities, thus allowing greater tolerability and efficacy…Read more

day: Conference Day Two